These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 23051633

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R.
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.
    Arnon R, Aharoni R.
    J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA, Kim E, Moodie J.
    Int J Nanomedicine; 2006 Nov; 1(3):283-9. PubMed ID: 17717969
    [Abstract] [Full Text] [Related]

  • 13. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.
    Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H, Friedman N, Arnon R.
    J Neuroimmunol; 2010 Aug 25; 225(1-2):100-11. PubMed ID: 20554028
    [Abstract] [Full Text] [Related]

  • 14. Immunomodulation by the copolymer glatiramer acetate.
    Arnon R, Sela M.
    J Mol Recognit; 2003 Aug 25; 16(6):412-21. PubMed ID: 14732933
    [Abstract] [Full Text] [Related]

  • 15. Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.
    Maier K, Kuhnert AV, Taheri N, Sättler MB, Storch MK, Williams SK, Bähr M, Diem R.
    Am J Pathol; 2006 Oct 25; 169(4):1353-64. PubMed ID: 17003491
    [Abstract] [Full Text] [Related]

  • 16. Neurodegeneration in autoimmune CNS inflammation.
    Herz J, Zipp F, Siffrin V.
    Exp Neurol; 2010 Sep 25; 225(1):9-17. PubMed ID: 19961850
    [Abstract] [Full Text] [Related]

  • 17. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
    Jee Y, Liu R, Bai XF, Campagnolo DI, Shi FD, Vollmer TL.
    Int Immunol; 2006 Apr 25; 18(4):537-44. PubMed ID: 16481342
    [Abstract] [Full Text] [Related]

  • 18. Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.
    Van Kaer L.
    Exp Neurol; 2011 Jan 25; 227(1):19-23. PubMed ID: 20969865
    [Abstract] [Full Text] [Related]

  • 19. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
    Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS.
    CNS Drugs; 2011 May 25; 25(5):401-14. PubMed ID: 21476611
    [Abstract] [Full Text] [Related]

  • 20. T-cell-mediated disruption of the neuronal microtubule network: correlation with early reversible axonal dysfunction in acute experimental autoimmune encephalomyelitis.
    Shriver LP, Dittel BN.
    Am J Pathol; 2006 Sep 25; 169(3):999-1011. PubMed ID: 16936273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.